TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31809418

Group type: EXPERIMENTAL
Intervention: Radiographic Union Score for Hip (RUSH) at 3 months
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Radiographic Union Score for Hip (RUSH) at 6 months
Number of subjects: 734
Study: 29530262

Group type: EXPERIMENTAL
Intervention: Cool Little Kids Online program (CBT-based, eight modules)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Wait-list group (control)
Number of subjects: 433
Study: 26927445

Group type: EXPERIMENTAL
Intervention: Sodium-glucose co-transporter-2 inhibitors
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 26155597

Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 3141

Group type: COMPARATOR
Intervention: NET-EN
Number of subjects: 3141

Group type: EXPERIMENTAL
Intervention: DMPA (among HSV-2 seropositive women)
Number of subjects: 3141

Group type: COMPARATOR
Intervention: NET-EN (among HSV-2 seronegative women)
Number of subjects: 3141
Study: 23102798

Group type: EXPERIMENTAL
Intervention: EE 30 mcg/CMA 2 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: EE 30 mcg/LNG 150 mcg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (nonhormonal contraceptive method)
Number of subjects: 64
Study: 20576732

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate 50/500 μg bid (SFC)
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Tiotropium 18 μg once daily (Tio)
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: SFC
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Tio
Number of subjects: 1323
Study: 18349781

Group type: EXPERIMENTAL
Intervention: New external fixation components
Number of subjects: 96

Group type: COMPARATOR
Intervention: Refurbished external fixation components
Number of subjects: 96
Study: 16814402

Group type: EXPERIMENTAL
Intervention: Partial tonsil resection/tonsillotomy (TT)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Full tonsillectomy (TE)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pain relievers (opioids, paracetamol, diclofenac)
Number of subjects: 92
Study: 12488379

Group type: EXPERIMENTAL
Intervention: i.v. PCA morphine (dose, 1 mg; lockout interval, 8 min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular s.c. morphine injections
Number of subjects: 40
Study: 10466476

Group type: EXPERIMENTAL
Intervention: High salt (NaCl = 240 mmol/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times daily)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Chronic high NaCl and Indomethacin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Chronic high NaCl
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Chronic high NaCl in ISH group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Indomethacin in normotensive individuals
Number of subjects: 31
Study: 8706194

Group type: EXPERIMENTAL
Intervention: Sublingual triazolam 0.2 mg (T)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Peroral diazepam 10 mg (D)
Number of subjects: 81
Study: 2082487

Group type: EXPERIMENTAL
Intervention: Dipyridamole 100 mg q.i.d. starting 2 days before surgery, followed by aspirin 325 mg t.i.d. plus dipyridamole 75 mg t.i.d. 7 hours after surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiplatelet regimen (dipyridamole and aspirin)
Number of subjects: 0
Study: 346168

Group type: EXPERIMENTAL
Intervention: 3% adenine arabinoside (Ara‐A) in petrolatum ointment base applied four times daily for one week
Number of subjects: 22

Group type: COMPARATOR
Intervention: Base alone applied four times daily for one week
Number of subjects: 22
Study: 31610811

Group type: EXPERIMENTAL
Intervention: Intention to leave
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Dissatisfaction with educational opportunities
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Poor pays and benefits
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Lack of recognition
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Poor working environments
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: High workload
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Low affective commitment
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Being unmarried
Number of subjects: 336
Study: 27838323

Group type: EXPERIMENTAL
Intervention: Grass SLIT-tablet (MK-7243; ≤2800 bioequivalent allergen units/75,000 SQ-T dose)
Number of subjects: 2497

Group type: EXPERIMENTAL
Intervention: Short ragweed SLIT-tablet (MK-3641; ≤12 Amb a 1-U)
Number of subjects: 2497

Group type: EXPERIMENTAL
Intervention: House dust mite SLIT-tablet (MK-8237; ≤12 SQ-HDM)
Number of subjects: 2497

Group type: COMPARATOR
Intervention: Placebo (for all SLIT-tablet trials)
Number of subjects: 2497
Study: 26692201

Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulfate (BEAM trial)
Number of subjects: 289
Study: 25086152

Group type: EXPERIMENTAL
Intervention: SmartConsent (personalized informed consent generated through EHR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard consent (control group)
Number of subjects: 50
Study: 22071367

Group type: EXPERIMENTAL
Intervention: Low intensity pain
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High intensity pain
Number of subjects: 60
Study: 19259813

Group type: EXPERIMENTAL
Intervention: 5 cm H(2)O of positive end-expiratory pressure maintained until extubation (Group I)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Positive end-expiratory pressure (PEEP) of 5 cm H(2)O increased to 14 cm H(2)O every 20 min for 2 min during cross clamp (Group II)
Number of subjects: 32
Study: 17763840

Group type: EXPERIMENTAL
Intervention: 3 x 10 min sessions per day (n = 9)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1 x 30 min session per day (n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Matched time-control group (n = 10)
Number of subjects: 18
Study: 16283847

Group type: EXPERIMENTAL
Intervention: Conventional laparoscopic instruments
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: daVinci Robotic System
Number of subjects: 20

Group type: COMPARATOR
Intervention: Robotics
Number of subjects: 20
Study: 12027488

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite cement
Number of subjects: 18

Group type: COMPARATOR
Intervention: Kapandji wiring
Number of subjects: 18
Study: 9807337

Group type: EXPERIMENTAL
Intervention: Geriatric nursing education workshop
Number of subjects: 43
Study: 8689980

Group type: EXPERIMENTAL
Intervention: Halofantrine
Number of subjects: 335

Group type: COMPARATOR
Intervention: Metakelfin
Number of subjects: 335
Study: 31613323

Group type: EXPERIMENTAL
Intervention: Ongoing anticholinergic medication
Number of subjects: 510
Study: 30120283

Group type: EXPERIMENTAL
Intervention: 15 minutes of acute exergaming (physical activity of moderate intensity)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control condition (sedentary)
Number of subjects: 46
Study: 27452270

Group type: EXPERIMENTAL
Intervention: OFD + PRF + 1.2% RSV gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: OFD + PRF
Number of subjects: 90

Group type: COMPARATOR
Intervention: OFD alone
Number of subjects: 90
Study: 25681432

Group type: EXPERIMENTAL
Intervention: Supervised endurance exercise (14 wk, 3-4 days/wk, 120-240 min/wk, 65-85% of maximum heart rate)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 23113643

Group type: EXPERIMENTAL
Intervention: fermented bilberry extract (400 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 21436726

Group type: EXPERIMENTAL
Intervention: Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 (2×10(11) CFU/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19427372

Group type: EXPERIMENTAL
Intervention: GSM 890 MHz signal exposure for 30 minutes
Number of subjects: 41
Study: 16398734

Group type: EXPERIMENTAL
Intervention: 5 percent human albumin plus Ringer's lactate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 42
Study: 15276691

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Perospirone
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 77
Study: 11418283

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 105
Study: 9249109

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl infusion (Group III)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (Group II)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (Group I)
Number of subjects: 50
Study: 8493215

Group type: EXPERIMENTAL
Intervention: GM-CSF (E. coli) 250 micrograms/m2/day
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 2950015

Group type: EXPERIMENTAL
Intervention: misoprostol (a prostaglandin E1 analogue)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 31899746

Group type: EXPERIMENTAL
Intervention: Deceptive placebo (DP)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) with positive expectancies
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) with raised hope
Number of subjects: 117

Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 117
Study: 28981303

Group type: EXPERIMENTAL
Intervention: Affective mental contrasting intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Instrumental mental contrasting intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard mental contrasting intervention
Number of subjects: 110
Study: 27451347

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids and severity-specific inhaled bronchodilator therapy
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Viral detection
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Fever
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Baseline PRAM score
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Oxygen saturation < 92%
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Presence of symptoms between exacerbations
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Viral detection in preschoolers
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Fever in preschoolers
Number of subjects: 973
Study: 24661661

Group type: COMPARATOR
Intervention: CIMRT (75.6 Gy in 1.8‐Gy fractions)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: HIMRT (72 Gy in 2.4‐Gy fractions)
Number of subjects: 203
Study: 21971082

Group type: EXPERIMENTAL
Intervention: Lyophilized powder of enzymolyzed honeybee larvae
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20417770

Group type: EXPERIMENTAL
Intervention: Cell saver group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 18626172

Group type: EXPERIMENTAL
Intervention: Acupuncture (A + B)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (B)
Number of subjects: 13
Study: 15923168

Group type: EXPERIMENTAL
Intervention: Chemotherapy for multiple myeloma
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Gel filtration of serum
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Immunohistochemical stains
Number of subjects: 1
Study: 12766964

Group type: EXPERIMENTAL
Intervention: MedioStar laser
Number of subjects: 29

Group type: COMPARATOR
Intervention: LightSheer laser
Number of subjects: 29
Study: 10348279

Group type: EXPERIMENTAL
Intervention: Irradiation and Misonidazole
Number of subjects: 120

Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 120
Study: 8522640

Group type: EXPERIMENTAL
Intervention: Ro 41-3696 at doses of 10 mg and 30 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ro 41-3696
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ro 41-3696 and Ro 41-3290
Number of subjects: 36
Study: 1682684

Group type: EXPERIMENTAL
Intervention: B-subunit/whole-cell cholera vaccine (BS-WC)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study: 6963076

Group type: EXPERIMENTAL
Intervention: Oral PGE2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous PGE2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGE2 tablets intravaginally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 0
Study: 31320694

Group type: EXPERIMENTAL
Intervention: Greater quantity and variety of snack items
Number of subjects: 1299

Group type: COMPARATOR
Intervention: Box size manipulation
Number of subjects: 1299

Group type: COMPARATOR
Intervention: Quantity/variety of items
Number of subjects: 1299
Study: 27936376

Group type: EXPERIMENTAL
Intervention: Peer Network Counseling (PNC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 46
Study: 27751553

Group type: EXPERIMENTAL
Intervention: Active stimulation (diaphragm pacing)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 74
Study: 24359932

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study: 22866289

Group type: EXPERIMENTAL
Intervention: NAI (variable‐thread design, NobelActive internal connection)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: NAE (variable‐thread design, NobelActive external connection)
Number of subjects: 177

Group type: COMPARATOR
Intervention: NR (standard tapered design, NobelReplace tapered groovy)
Number of subjects: 177
Study: 18403375

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Working
Number of subjects: 312
Study: 17522399

Group type: EXPERIMENTAL
Intervention: Advanced life support (ALS) treatment, including endotracheal intubation and intravenous drugs, administered to 56.6% of patients during the second phase.
Number of subjects: 8138

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation performed in 1.4% of patients during the second phase.
Number of subjects: 8138

Group type: EXPERIMENTAL
Intervention: Intravenous drugs administered to 15.0% of patients during the second phase.
Number of subjects: 8138

Group type: EXPERIMENTAL
Intervention: Use of nebulized salbutamol and sublingual nitroglycerin increased during the second phase.
Number of subjects: 8138
Study: 14742379

Group type: EXPERIMENTAL
Intervention: memantine (30 mg/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 11167376

Group type: EXPERIMENTAL
Intervention: Active treatment with polyurethane-coated cotton encasings for bedding
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with cotton covers
Number of subjects: 40
Study: 9459625

Group type: EXPERIMENTAL
Intervention: Cytokine treatment (interferon-alpha or interferon-beta, either alone or in combination with interleukin-2 or antineoplastic agents)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (patients suffering from ATD)
Number of subjects: 166
Study: 7949265

Group type: EXPERIMENTAL
Intervention: UDCA (10 mg/kg/day for 15-20 days)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CDCA (15 mg/kg/day for 15-20 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Untreated subjects (control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CDCA treated group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: UDCA treated group
Number of subjects: 28
Study: 2851180

Group type: COMPARATOR
Intervention: Cisplatin (120 mg/m2 on day 1)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Cisplatin (120 mg/m2 on day 1) plus etoposide (VP‐16) (100 mg/m2 on days 1‐3)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Cisplatin (120 mg/m2 on day 1) plus etoposide (VP‐16) (100 mg/m2 on days 1‐3) plus mitomycin C (10 mg/m2 on days 1, 21, and 42; then every 6 weeks for a maximum dose of 100 mg)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Combination therapy (cisplatin and etoposide)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Single agent (cisplatin)
Number of subjects: 156
Study: 31373868

Group type: EXPERIMENTAL
Intervention: SPIRIT in person (in a private room in a memory clinic)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SPIRIT remote (via videoconferencing from home)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SPIRIT (both in person and remote)
Number of subjects: 23
Study: 28591061

Group type: EXPERIMENTAL
Intervention: Elastic resistance exercise training (RET) for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no RET intervention)
Number of subjects: 46
Study: 25539672

Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR) followed by radiofrequency ablation (RFA)
Number of subjects: 508
Study: 23908490

Group type: EXPERIMENTAL
Intervention: Investigational tuberculosis vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG-immunized HIV-infected adults
Number of subjects: 0
Study: 21378711

Group type: EXPERIMENTAL
Intervention: Reamberin in a dose of 400-800 ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 19077155

Group type: EXPERIMENTAL
Intervention: Purely cancellous bone (PCB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Corticocancellous iliac bone grafts (50% cancellous and 50% cortical)
Number of subjects: 15
Study: 17287313

Group type: EXPERIMENTAL
Intervention: MenC‐TT plus DTPa‐HBV‐IPV/Hib
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Hib‐MenC‐TT plus DTPa‐HBV‐IPV
Number of subjects: 520

Group type: COMPARATOR
Intervention: MenC‐CRM(197) plus DTPa‐HBV‐IPV/Hib
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Booster doses
Number of subjects: 520
Study: 15534017

Group type: EXPERIMENTAL
Intervention: Mutual support intervention (N=32)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Psychoeducation intervention (N=33)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard care (N=31)
Number of subjects: 96
Study: 12151142

Group type: EXPERIMENTAL
Intervention: Regular diet as the first postoperative meal
Number of subjects: 254

Group type: COMPARATOR
Intervention: Clear liquid diet as the first postoperative meal
Number of subjects: 254
Study: 9880125

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 1917
Study: 7911677

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative chemotherapy (5-drug-combination + tamoxifen)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Pre- and postoperative radiotherapy
Number of subjects: 105
Study: 2680432

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 1244627

Group type: EXPERIMENTAL
Intervention: Mismatch tones (5%, 25%, or 100% different in pitch)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reading a book (control condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responding with a button press (active condition)
Number of subjects: 0
Study: 31752624

Group type: EXPERIMENTAL
Intervention: Visual metaphor with death-based fear appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual metaphor with appearance-based fear appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal metaphor with death-based fear appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal metaphor with appearance-based fear appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Need for cognition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived message effectiveness
Number of subjects: 0
Study: 31373827

Group type: EXPERIMENTAL
Intervention: Healing meditation program (8 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (standard treatment + observation)
Number of subjects: 55
Study: 27492888

Group type: EXPERIMENTAL
Intervention: Single-visit program (multidisciplinary team visit, fall risk assessment with feedback, fall prevention lecture)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Year-round comprehensive program (visits every 3 months)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Modified version of the single-visit program
Number of subjects: 603
Study: 26271869

Group type: EXPERIMENTAL
Intervention: 0.2% CHX‐alcohol
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: 0.2% CHX‐alcohol‐free
Number of subjects: 319

Group type: COMPARATOR
Intervention: Brushing alone
Number of subjects: 319
Study: 21925749

Group type: EXPERIMENTAL
Intervention: Conventional cardiovascular risk factors (obesity, blood pressure, lipids, smoking habits)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Novel cardiovascular risk factors (PAI-1, platelet count, total homocysteine, C-reactive protein)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Markers of vascular damage (carotid IMT, vWF, e‐selectin)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Age, obesity, and conventional risk factors
Number of subjects: 441

Group type: COMPARATOR
Intervention: Novel cardiovascular risk factors
Number of subjects: 441
Study: 22673924

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg daily)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 U daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Dietary advice (control)
Number of subjects: 67
Study: 19481022

Group type: EXPERIMENTAL
Intervention: PPI (pantoprazole 40 mg/day)
Number of subjects: 33
Study: 17372321

Group type: EXPERIMENTAL
Intervention: Post-absorptive exercise (at approximately 60% of VO2max for 45 minutes)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Postprandial exercise (at approximately 60% of VO2max for 45 minutes)
Number of subjects: 7

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Post-absorptive exercise
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Postprandial exercise
Number of subjects: 7
Study: 15206014

Group type: EXPERIMENTAL
Intervention: Addition of a second opioid at low doses (initial equivalent dosage of 20% of previous therapy)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Addition of a second opioid at low doses
Number of subjects: 14
Study: 11444416

Group type: EXPERIMENTAL
Intervention: Chromium (400 microg/d as Cr pidolate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc (30 mg/d as Zn gluconate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined Zinc and Chromium supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0